Effects of momelotinib: A Synthesis of Findings from 28 Studies

  1. Home
  2. Effects of momelotinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of momelotinib: A Synthesis of Findings from 28 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of momelotinib: A Synthesis of Findings from 28 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

Momelotinib is an orally administered, small-molecule inhibitor that blocks JAK1, JAK2, and ACVR1. 24 、 12 、 20 、 3 、 14 、 2 、 26 、 1 、 17 In patients with myelofibrosis (MF), momelotinib has shown potential to reduce spleen size, improve symptoms, and potentially improve anemia. 24 、 4 、 15 、 22 、 21 、 5 、 6 、 11 、 10 、 28 、 27 、 13 Momelotinib has been shown to be superior to danazol in preventing anemia worsening and in controlling MF-associated signs and symptoms, such as spleen size, in MF patients previously treated with JAK inhibitors. 22 Momelotinib has been shown to inhibit JAK1, JAK2, and ACVR1, which sets it apart from other JAK inhibitors. 12 、 8 、 14 、 3 Momelotinib is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. 22 Momelotinib is currently awaiting FDA approval as a potential treatment for MF patients to reduce spleen size and improve symptoms. 3 、 15 、 28 Further research is being conducted on momelotinib as a potential treatment to improve anemia in MF patients. 3 Momelotinib may also be helpful for treating anemia in other diseases associated with MF and for developing other targeted therapies. 3 The safety and efficacy of momelotinib are being evaluated in ongoing Phase III clinical trials. 22

Benefits and Risks

Benefit Summary

Momelotinib has shown potential to reduce spleen size, improve symptoms, and potentially improve anemia in patients with myelofibrosis (MF). 24 、 4 、 15 、 22 、 21 、 5 、 6 、 11 、 10 、 28 、 27 、 13 Momelotinib has been shown to be superior to danazol in preventing anemia worsening and in controlling MF-associated signs and symptoms, such as spleen size, in MF patients previously treated with JAK inhibitors. 22 Momelotinib has been shown to inhibit JAK1, JAK2, and ACVR1, which sets it apart from other JAK inhibitors. 12 、 8 、 14 、 3 Momelotinib is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. 22 Momelotinib is currently awaiting FDA approval as a potential treatment for MF patients to reduce spleen size and improve symptoms. 3 、 15 、 28 Further research is being conducted on momelotinib as a potential treatment to improve anemia in MF patients. 3 Momelotinib may also be helpful for treating anemia in other diseases associated with MF and for developing other targeted therapies. 3 The safety and efficacy of momelotinib are being evaluated in ongoing Phase III clinical trials. 22

Risk Summary

Momelotinib may cause several side effects. 3 、 26 、 1 The most common side effects are diarrhea, peripheral neuropathy, thrombocytopenia, and dizziness. 4 、 5 、 2 These side effects can usually be improved by reducing the momelotinib dose or stopping momelotinib treatment. 2 Dosage adjustments may be necessary for patients with reduced liver or kidney function. 1

Research Comparisons

Research Similarities

Momelotinib is currently awaiting FDA approval as a potential treatment for MF patients to reduce spleen size and improve symptoms. 3 、 15 、 28 Further research is being conducted on momelotinib as a potential treatment to improve anemia in MF patients. 3 Momelotinib may also be helpful for treating anemia in other diseases associated with MF and for developing other targeted therapies. 3 The safety and efficacy of momelotinib are being evaluated in ongoing Phase III clinical trials. 22

Research Differences

Momelotinib's efficacy and safety have been evaluated in various studies, but the results may vary between them. 3 、 26 、 1 For instance, while some studies have shown a substantial effect of momelotinib on anemia, others have reported more limited improvements. 3 、 22 In addition, certain studies suggest that momelotinib has fewer side effects, while others describe more frequent adverse effects. 2 These variations in findings can be attributed to several factors, such as methodological differences in studies, variations in the characteristics of study participants, and differences in momelotinib dosage. 3 、 2

Consistency and Inconsistencies of Results

Momelotinib has shown potential to reduce spleen size, improve symptoms, and potentially improve anemia in patients with myelofibrosis (MF). 24 、 4 、 15 、 22 、 21 、 5 、 6 、 11 、 10 、 28 、 27 、 13 However, momelotinib may cause several side effects. 3 、 26 、 1 The most common side effects are diarrhea, peripheral neuropathy, thrombocytopenia, and dizziness. 4 、 5 、 2 These side effects can usually be improved by reducing the momelotinib dose or stopping momelotinib treatment. 2 Dosage adjustments may be necessary for patients with reduced liver or kidney function. 1 The consistency and inconsistencies of these results suggest that momelotinib's effects and the risk of side effects may vary between patients. 2

Real-world Application and Considerations

Momelotinib is currently awaiting FDA approval as a potential treatment for MF patients to reduce spleen size and improve symptoms. 3 、 15 、 28 Further research is being conducted on momelotinib as a potential treatment to improve anemia in MF patients. 3 Momelotinib may also be helpful for treating anemia in other diseases associated with MF and for developing other targeted therapies. 3 The safety and efficacy of momelotinib are being evaluated in ongoing Phase III clinical trials. 22 While momelotinib may be prescribed to MF patients, it may not be suitable for all of them. 5 Momelotinib's dosage may vary between patients, and the risk of side effects can also vary. 2 It's crucial to consult a doctor before taking momelotinib. 5

Current Research Limitations

Momelotinib has shown potential to reduce spleen size, improve symptoms, and potentially improve anemia in patients with myelofibrosis (MF). 24 、 4 、 15 、 22 、 21 、 5 、 6 、 11 、 10 、 28 、 27 、 13 However, momelotinib may cause several side effects. 3 、 26 、 1 The most common side effects are diarrhea, peripheral neuropathy, thrombocytopenia, and dizziness. 4 、 5 、 2 These side effects can usually be improved by reducing the momelotinib dose or stopping momelotinib treatment. 2 Dosage adjustments may be necessary for patients with reduced liver or kidney function. 1 Research on momelotinib is still in its early stages, and the long-term effects and safety of momelotinib have yet to be fully understood. 3 、 26 、 1

Future Research Directions

Further research on momelotinib is needed to understand its long-term effects and safety, and to guide its optimal use in treating MF. 3 、 26 、 1 Studies comparing momelotinib's efficacy and safety to other treatments for MF are crucial. 20 Furthermore, identifying biomarkers to predict momelotinib's effects is essential due to the potential variability in responses among MF patients. 2

Conclusion

Momelotinib is currently awaiting FDA approval as a potential treatment for MF patients to reduce spleen size and improve symptoms. 3 、 15 、 28 Further research is being conducted on momelotinib as a potential treatment to improve anemia in MF patients. 3 Momelotinib may also be helpful for treating anemia in other diseases associated with MF and for developing other targeted therapies. 3 The safety and efficacy of momelotinib are being evaluated in ongoing Phase III clinical trials. 22 MF patients should stay informed about the latest research on momelotinib and consult with their doctor to choose the most appropriate treatment. 5

Keywords
Benefit Keywords
myelofibrosis treatment
1
Myelofibrosis treatment
Survival improvement
2
Anemia reduction
MF treatment
3
Therapeutic activity for myelofibrosis
Tolerable
4
Reduces spleen size
Reduces symptom burden
6
Improved splenomegaly
MF management
Survival advantage
7
Anti-proliferative effect
JAK2 inhibition
Leukemic engraftment reduction
MPN treatment
Survival extension
8
Effective treatment
9
Improved quality of life
Symptom control
10
MF treatment
11
Anemia treatment
MF symptom relief
12
Myelofibrosis treatment
13
Treats glioblastoma multiforme
14
Improved myelofibrosis management
15
JAK2/FLT3 inhibition
17
Improved MF treatment
Reduced bone marrow fibrosis
Survival prolongation
18
AML treatment
19
Spleen volume reduction
Symptom score reduction
20
MF treatment
21
Improved hemoglobin
Improved symptoms
Treats myelofibrosis
22
Lymphoid cancer treatment
23
Symptom control
24
Antifibrotic
25
MF treatment
26
Effective management
Spleen reduction
27
Improved splenomegaly
Symptom control
28
Risk Keywords
hepatic impairment
1
Anaemia
Peripheral neuropathy
Spleen response
2
Diarrhea
Dizziness
Peripheral neuropathy
Thrombocytopenia
4
Anemia
Infection
Thrombocytopenia
5
Myelosuppression
Suboptimal response
6
Cytopenias
Lack of anti-clonal effect
Ruxolitinib failure
7
Dizziness
Fatigue
Headache
Nausea
Peripheral neuropathy
Somnolence
9
Complications due to cytopenias
Progression without transformation
10
Blast phase transformation
Bone marrow fibrosis
Cytopenias
Driver mutation allele burden
11
Anemia
16
Severe thrombocytopenia
18
Anemia
Thrombopenia
20
Anemia
Thrombocytopenia
21
Dose-dependent toxicities
24
Liver disease
25
Loss of response
Toxicity
26
Disease progression
28
Literature analysis of 28 papers
Positive Content
26
Neutral Content
1
Negative Content
1
Article Type
1
1
1
11
28
1.

Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.

Author: XinYan, KawashimaJun, WengWinnie, KwanEllen, TarnowskiThomas, SilvermanJeffrey A

myelofibrosis treatment
hepatic impairment

This study evaluated the pharmacokinetics of momelotinib, a Janus kinase 1/2 inhibitor, in subjects with hepatic or renal impairment. The study found that dose adjustment is not necessary for momelotinib in patients with renal impairment or mild to moderate hepatic impairment. However, the dose should be reduced in patients with severe hepatic impairment.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.

Author: AbdelrahmanRamy A, BegnaKebede H, Al-KaliAref, HoganWilliam J, LitzowMark R, PardananiAnimesh, TefferiAyalew

Myelofibrosis treatment
Survival improvement
Anaemia
Peripheral neuropathy
Spleen response

Momelotinib treatment for myelofibrosis was associated with peripheral neuropathy in 44% of patients, which was significantly associated with treatment response and longer survival.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.

Author: WintonElliott F, KotaVamsi

Anemia reduction
MF treatment

Myelofibrosis (MF) is a blood-forming system malignancy. This article discusses the use of JAK2 inhibitors for treating MF, focusing on momelotinib, a JAK1/2 inhibitor that unexpectedly resulted in anemia reduction in MF patients during Phase I/II trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Author: GuptaVikas, MesaRuben A, DeiningerMichael W N, RiveraCandido E, SirhanShireen, BrachmannCarrie Baker, CollinsHelen, KawashimaJun, XinYan, VerstovsekSrdan

Therapeutic activity for myelofibrosis
Tolerable
Diarrhea
Dizziness
Peripheral neuropathy
Thrombocytopenia

Momelotinib is a JAK1/JAK2 inhibitor that is effective in myelofibrosis patients. A phase 1/2 study of momelotinib with twice-daily dosing in 61 patients with myelofibrosis identified 200 mg twice daily as the optimal dose. The most frequent adverse events were diarrhea (45.9%), peripheral neuropathy (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%). The response assessment demonstrated spleen response by palpation of 72% (36/50) and anemia response of 45% (18/40). The results suggest tolerability and a potential therapeutic activity of momelotinib for subjects.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.

Author: GotlibJason

Reduces spleen size
Reduces symptom burden
Myelosuppression
Suboptimal response

This review discusses the development of JAK inhibitors for the treatment of myelofibrosis (MF). Ruxolitinib is approved for treating MF, and other JAK inhibitors, such as fedratinib, momelotinib, and pacritinib, are in advanced phases of trial investigation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms.

Author: KongTim, YuLaYow, LaranjeiraAngelo B A, FisherDaniel A C, HeFan, CoxMaggie J, OhStephen T

Anti-proliferative effect
JAK2 inhibition
Leukemic engraftment reduction
MPN treatment
Survival extension

JAK2 inhibitors are medications used to treat myeloproliferative neoplasm (MPN). This study compared the effects of four JAK2 inhibitors (ruxolitinib, fedratinib, pacritinib, and momelotinib) on MPN cells in the laboratory. The study found that all four inhibitors effectively suppressed JAK-STAT signaling, but they also had different effects on other pathways, which may explain their different clinical profiles.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

9.

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.

Author: VerstovsekSrdan, CourbyStephane, GriesshammerMartin, MesaRuben A, BrachmannCarrie Baker, KawashimaJun, MaltzmanJulia D, ShaoLixin, XinYan, HuangDaniel, BajelAshish

Effective treatment
Dizziness
Fatigue
Headache
Nausea
Peripheral neuropathy
Somnolence

This phase 2 study evaluated the efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). The study was terminated due to limited efficacy, with only two out of 39 patients achieving the primary endpoint. While momelotinib demonstrated stable plasma levels, it was associated with frequent adverse events, including headache, dizziness, and fatigue.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Cytopenic myelofibrosis: prevalence, relevance, and treatment.

Author: VachhaniPankit, VerstovsekSrdan, BosePrithviraj

Myelofibrosis treatment

This study explores cytopenic myelofibrosis, a phenotype of myelofibrosis characterized by low blood counts and worse outcomes.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Treatment of anemia in myelofibrosis: focusing on Novel Therapeutic Options.

Author: DavulcuEren Arslan, OğuzMerve Beyza, KılıçEmre, EşkazanAhmet Emre

Anemia

Myelofibrosis, a clonal myeloproliferative neoplasm, is associated with various factors that contribute to anemia, including increased bone marrow fibrosis, extramedullary hematopoiesis, and abnormal cytokine production.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

17.

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.

Author: LiYingxiu, YeTianyu, XuLe, DongYuhong, LuoYong, WangChu, HanYufei, ChenKe, QinMingze, LiuYajing, ZhaoYanfang

JAK2/FLT3 inhibition

Hybridization strategy was used to design a series of 4-piperazinyl-2-aminopyrimidine derivatives with dual inhibitory activity against JAK2 and FLT3 enzymes. Compound 14j showed the most balanced in vitro activity and was selected as a promising JAK2/FLT3 dual inhibitor.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

18.

Novel strategies for challenging scenarios encountered in managing myelofibrosis.

Author: BosePrithviraj, MesaRuben A

Improved MF treatment
Reduced bone marrow fibrosis
Survival prolongation
Severe thrombocytopenia

While JAK inhibitors offer benefits for myelofibrosis, there are limitations and a need for alternative or synergistic approaches to address unmet needs. Promising drug development efforts in this area offer hope for improved treatment outcomes in the future.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

19.

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Author: LiuSuhu, MarnethAnna E, AlexeGabriela, WalkerSarah R, GandlerHelen I, YeDarwin Q, LabellaKatherine, MathurRadhika, TonioloPatricia A, TillgrenMichelle, GokhalePrafulla C, BarbieDavid, MullallyAnn, StegmaierKimberly, FrankDavid A

AML treatment

IKBKE, a noncanonical IkB kinase, is overexpressed in acute myeloid leukemia (AML) cells and represents a promising therapeutic target. Inhibition of IKBKE/TBK1 by either knockdown or pharmacological compounds induced apoptosis and reduced the viability of AML cells.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.

Author: SureauLéa, OrvainCorentin, IanottoJean-Christophe, UgoValérie, KiladjianJean-Jacques, Luque PazDamien, RiouJérémie

Spleen volume reduction
Symptom score reduction
Anemia
Thrombopenia

A network meta-analysis of JAK inhibitors in myelofibrosis found that momelotinib and fedratinib showed comparable efficacy to ruxolitinib in first-line therapy. Pacritinib was less effective in first-line but seemed effective in second-line after ruxolitinib. Fedratinib and ruxolitinib, both FDA approved, are valuable options for splenomegaly and constitutional symptoms. Momelotinib is a promising alternative due to its positive effect on anemia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

21.

Novel therapeutics for myelofibrosis.

Author: LeeSung-Eun

MF treatment
Anemia
Thrombocytopenia

Myelofibrosis (MF) is a progressive myeloid neoplasm. While JAK2 inhibitors like ruxolitinib and fedratinib have been approved, their use is limited due to adverse effects. This review discusses new MF treatments under development, including pacritinib, momelotinib, and agents targeting bromodomain and extra-terminal protein, Bcl-xL, and phosphatidylinositol-3-kinase delta.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.

Author: VerstovsekSrdan, ChenChih-Cheng, EgyedMiklós, EllisMartin, FoxLaura, GohYeow T, GuptaVikas, HarrisonClaire, KiladjianJean-Jacques, LazaroiuMihaela C, MeadAdam, McLornanDonal, McMullinMary F, OhStephen T, PerkinsAndrew, PlatzbeckerUwe, ScheidChristof, VannucchiAlessandro, YoonSung-Soo, KowalskiMark M, MesaRuben A

Improved hemoglobin
Improved symptoms
Treats myelofibrosis

Momelotinib (MMB) is a JAK inhibitor that has been investigated for the treatment of myelofibrosis (MF). MMB possesses a differentiated pharmacological and clinical profile by inhibiting JAK1, JAK2, and ACVR1. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

24.

The safety of JAK kinase inhibitors for the treatment of myelofibrosis.

Author: ColtroGiacomo, VannucchiAlessandro M

Symptom control
Dose-dependent toxicities

Janus kinase inhibitors (JAKi) have revolutionized the treatment of myelofibrosis but can have dose-dependent toxicities, making dose optimization and treatment discontinuation challenging.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

25.

Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.

Author: DatNinh Quoc, ThuyLe Thi Thanh, HieuVu Ngoc, HaiHoang, HoangDinh Viet, Thi Thanh HaiNguyen, ThuyTuong Thi Van, KomiyaTohru, RomboutsKrista, DongMinh Phuong, HanhNgo Vinh, HoangTruong Huu, Sato-MatsubaraMisako, DaikokuAtsuko, KadonoChiho, OikawaDaisuke, YoshizatoKatsutoshi, TokunagaFuminori, PinzaniMassimo, KawadaNorifumi

Antifibrotic
Liver disease

This study found that cytoglobin (CYGB), a respiratory protein expressed in hepatic stellate cells (HSCs), has antifibrotic properties. CYGB-deficient mice showed exacerbated liver damage and fibrosis, while CYGB-overexpressing mice showed attenuated liver damage and fibrosis. Recombinant human CYGB (His-CYGB) was shown to be endocytosed by HSCs and significantly reduced ROS formation, collagen production, and α-smooth muscle actin expression. Intravenous injection of His-CYGB suppressed liver inflammation, fibrosis, and oxidative cell damage in mice with advanced liver cirrhosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

Author: SongMoo-Kon, ParkByeong-Bae, UhmJi-Eun

Effective management
Spleen reduction

Splenomegaly in myelofibrosis is associated with splenic extramedullary hematopoiesis, and JAK inhibitors are effective for spleen reduction.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.